Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Commission has granted orphan drug designation to RE-024, Retrophin's novel investigational phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN), a rare and life-threatening genetic disorder with no approved treatment option.
Subscribe to our email newsletter
"Receiving orphan drug status in the EU is another encouraging step in the development of RE-024 for the treatment of PKAN," said Alvin Shih, M.D., executive vice president and head of research & development for Retrophin.
"Without an approved therapy, many people living with PKAN currently face a significant burden of illness. We look forward to continuing our development of RE-024 with the ultimate goal of delivering an effective therapeutic option to these patients."
In the European Union (EU), orphan drug designation is granted to a medicinal product intended to treat a life-threatening or chronically debilitating rare disease with no approved treatment option.
In the EU, a disease is designated as rare if it affects no more than five in 10,000 people. In addition to a 10-year period of EU market exclusivity upon product approval, orphan drug designation provides fee waivers, protocol assistance, and single marketing authorization under the centralized procedure that is valid in all EU countries.
In 2015, the U.S. Food and Drug Administration granted orphan drug designation to RE-024 for the treatment of PKAN, as well as Fast Track status, which is designed to facilitate the development and expedite the review of medicines to treat serious conditions with unmet medical needs in order to reach patients earlier.
About Pantothenate Kinase-Associated Neurodegeneration (PKAN)
Pantothenate kinase-associated neurodegeneration, or PKAN, is a rare, genetic, and life-threatening neurological disorder characterized by a host of progressively debilitating symptoms that typically begin in early childhood.
People suffering from PKAN may experience movement disorders such as dystonia (sustained muscle contraction leading to abnormal posture), rigidity, dysphagia (problems swallowing), twisting and writhing, and tremors, as well as visual impairment. Currently, there is no approved treatment option for PKAN, which is estimated to affect up to 5,000 people worldwide.
PKAN is caused by a mutation in the PANK2 gene, which encodes a critical protein that phosphorylates vitamin B5 (pantothenate) to phosphopantothenate. The disruption of this metabolic pathway ultimately leads to decreased levels of Coenzyme A (CoA), which plays an important role in many cellular functions.
About RE-024
RE-024 is a novel small molecule in Phase 1 clinical development as a phosphopantothenate replacement therapy for PKAN. Preclinical findings from studies of PANK-deficient animal models and cell lines suggest the ability of RE-024 to restore CoA levels.